The epidermal growth factor receptor (EGFR) serves as an attractive target for cancer molecular imaging and therapy. Our previous positron emission tomography (PET) 
F-FBEM-Z EGFR:1907 can discriminate between high and low EGFR-expression tumors and have the potential for patient selection for EGFR-targeted therapy. Compared with 64 Cu, 18 F may improve imaging of EGFR-expression and is more suitable for clinical application, but the labeling reaction of 18 F-FBEM-Z EGFR:1907 requires a long synthesis time. The aim of the present study is to develop a new generation of 18 F labeled affibody probes (Al 18 F-NOTA-Z EGFR:1907 and 18 F-CBT-Z EGFR:1907 ) and to determine whether they are suitable agents for imaging of EGFR expression. The first approach consisted of conjugating Z EGFR:1907 with NOTA and radiolabeling with Al 18 F to produce Al 18 F-NOTA-Z EGFR:1907 . In a second approach the prosthetic group 18 F-labeled-2-cyanobenzothiazole ( F-CBT-Z EGFR:1907 were completed successfully within 40 and 120 min with a decay-corrected yield of 15% and 41% using a 2-step, 1-pot reaction and 2-step, 2-pot reaction, respectively. Both probes bound to EGFR with low nanomolar affinity in A431 cells. Although 18 F-CBT-Z EGFR:1907 showed instability in vivo, biodistribution studies revealed rapid and high tumor accumulation and quick clearance from normal tissues except the bones. In contrast, Al 18 F-NOTA-Z EGFR:1907 demonstrated high in vitro and in vivo stability, high tumor uptake, and relative low uptake in most of the normal organs except the liver and kidneys at 3 h after injection. The specificity of both probes for A431 tumors was confirmed by their lower uptake on coinjection of unlabeled affibody. PET studies showed that Al F-labeling of affibody molecules were successfully developed as two model platforms using NOTA or CBT coupling to affibody molecules that contain an N-terminal cysteine. Al
■ INTRODUCTION
The epidermal growth factor receptor (EGFR) plays an important role in neoplastic processes of cell proliferation, inhibition of apoptosis, angiogenesis, and metastatic spread. 1 Overexpression of EGFR in tumors has been associated with resistance against conventional drug treatment and radiation and may predict poor prognosis. 2−4 Detection of EGFR expression by molecular imaging could be a useful tool for evaluation of antitumor drug effect, stratification of cancer patients for molecularly targeted therapy, and prognosis of cancer patients, as it could provide real time data with fewer false-negative results. 5 Affibody molecules are based on a 58 amino acid residue protein domain, derived from one of the IgG-binding domains of staphylococcal protein A, and has been engineered to be chemically stable and to bind target proteins with high affinity. 6, 7 Because of their small size (∼7 kDa) and high affinity, affibody molecules generally show fast and good tumor tissue penetration and accumulation, and rapid clearance from the blood, resulting in high imaging contrast within a short period (for example, 0.5−1 h) after injection. Antihuman epidermal growth factor receptor 2 (HER2) affibody molecules (Z HER2 ) and their derivatives have been radiolabeled with various radionuclides for imaging of tumors overexpressing HER2 in animal models. 7−10 Subsequently, 111 In-or 68 Ga-labeled Z HER2 have been successfully and safely used to visualize HER2-expressing tumors in patients with metastatic breast cancer. These clinical studies clearly demonstrate that affibody molecules have great potential to become a promising new class of cancer-targeting ligands for clinical translation. 11 Overall the previous preclinical and clinical studies encourage us to further develop clinical translatable affibody probes to image other tumor targets such as EGFR. 12, 13 We have previously reported the site-specific coupling of an anti-EGFR affibody molecule (Z EGFR:1907 ) with maleimidomonoamide-DOTA (MMA-DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7-trisaceticacid-10-maleimidoethylmonoamide) to produce the bioconjugate, DOTA-Z EGFR:1907 , that was radiolabeled with 64 Cu. 13 This conjugate allowed high-contrast imaging of EGFR-expressing xenografts. However, imaging of EGFR expression with affibody molecules and further clinical translation of them can be further improved by 18 (Figure 1 ). The in vitro properties and in vivo 
■ MATERIALS AND METHODS
General. MMA-NOTA was purchased from CheMatech Inc. (Dijon, France). Phosphate-buffered saline (PBS), high-glucose Dulbecco's modified eagle medium (DMEM), 10% fetal bovine serum (FBS), 1% penicillin−streptomycin, 0.1% trypsin, trypsin− EDTA, and TrypLE-Express were purchased from Invitrogen Life Technologies (Carlsbad, California). Dimethyl sulfoxide (DMSO) and acetonitrile (MeCN) were purchased from Fisher Scientific (Pittsburgh, Pennsylvania). Dimethylformamide (DMF), trifluoroacetic acid (TFA), thioanisole (TIS), ethanedithiol (EDT), ethylene-diamine-tetra-acetic acid (EDTA), tris(2-carboxyethyl)-phosphine hydrochloride (TCEP HCl), N,N-diisopropyl-ethylamine (DIPEA), ethyl acetate, dithiothreitol (DTT), mouse serum, and all other standard synthesis reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, Missouri). All chemicals were used without further purification.
The affibody molecules Ac-Cys-Z EGFR:1907 (Ac-CVDNK-
and Cys-Z EGFR:1907 (CVDNKFNKEMWAAWEEIRNLPNLNGWQMTAFI-ASLVDDPSQSANLLAEAKKLNDAQAPK-NH 2 ) were synthesized on a CS Bio CS336 instrument (CS Bio Company, Menlo Park, California) in our laboratory as previously described. 13 The purified peptide was dissolved in water, and the concentration was determined by amino acid analysis (Molecular Structure Facility, University of California, Davis, CA). Peptide purity and molecular mass were determined by analytic scale reversed-phase high-performance liquid chromatography (RP-HPLC, model: 3000 HPLC System, Dionex Corporation, Sunnyvale, California) and matrix-assisted laser desorption/ionization−time-offlight mass spectrometry (MALDI-TOF-MS, model: Perseptive Voyager-DE RP Biospectrometer, Framinghan, Massachusetts) or electrospray ionization mass spectrometry (ESI-MS, model: Micromass ZQ single quadrupole LC−MS, Milford, Massachusetts) as previously described. 13 The human epidermoid carcinoma cancer cell line A431 was obtained from the American Type Tissue Culture Collection (Manassas, Virginia). Female nude mice were purchased from Charles River Laboratories (Boston, Massachusetts).
Radiosynthesis of Al 18 F-NOTA-Z EGFR:1907 . The affibody molecule NOTA-Z EGFR:1907 was radiolabeled with 18 F according to a previously reported method 14, 15, 18 ( Figure 1A ). First, Ac-Cys-Z EGFR:1907 was conjugated with the bifunctional chelator MMA-NOTA using the method described below: Ac-Cys-Z EGFR:1907 was dissolved in freshly degassed phosphate buffer (0.1 M, pH 7.4) at a concentration of 1 mg/mL. Twenty equivalents of MMA-NOTA dissolved in DMSO (10 mM) were added. After mixing by vortexing for 2 h, the product was purified by RP-HPLC with a protein-and-peptide C4 column (Grace Vydac 214TP54, Columbia, Maryland) using a gradient system of solvent A (0.1% TFA/H 2 O) and solvent B (0.1%TFA/MeCN). The flow rate was 4 mL/min, with the mobile phase starting from 90% solvent A and 10% solvent B (0−3 min) to 35% solvent A and 65% solvent B at 33 min. Fractions containing the product were collected and lyophilized. F, and the desired product was purified with HPLC using the same elution gradient described for NOTA-Z EGFR:1907 purification. The HPLC fractions containing Al Cell Assays. Cell uptake and receptor saturation assays were performed as previously described with minor modifications. 13 Briefly, the EGFR positive A431 cell line was cultured in high glucose DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin−streptomycin. The cells were maintained in a humidified atmosphere of 5% CO 2 at 37°C, with the medium changed every 2 days. A 70−80% confluent monolayer was detached by 0.1% trypsin and dissociated into a single cell suspension for further cell culture.
Cell Uptake Assays. The A431 cells were washed three times with PBS and dissociated with 0.25% trypsin−EDTA. DMEM medium was then added to neutralize trypsin−EDTA. Cells were spun down and resuspended with serum-free DMEM. Cells ) were plated on 6-well plates 1 day before the experiment. Cells were washed with PBS three times. Serum-free DMEM (1 mL) was added to each well, followed by the addition of either Al In Vitro and In Vivo Stability. In vitro and in vivo stability were determined similarly to the procedures previously described with minor modifications. 12, 13 In Vitro Serum Stability Assay. Al 18 F-NOTA-Z EGFR:1907 (1.5−6.7 MBq) or 18 F-CBT-Z EGFR:1907 (2.2−7.4 MBq) was incubated in 0.5 mL of mouse serum for 1 and 2 h at 37°C. At each time point, the mixture was precipitated with 300 μL of ethanol and centrifuged at 16,000g for 2 min. The supernatant was transferred to a new Eppendrof tube, and DMF (300 μL) was added to precipitate the residue of serum protein. After centrifugation, the supernatant was acidified with 300 μL of buffer A (water + 0.1% TFA) and filtered using a 0.2 μm nylon Spin-X column (Corning Inc. Corning, New York). 18 F-CBT-Z EGFR:1907 (7.4 MBq) via a tail vein and euthanized at 1 h after injection. The tumors were removed and homogenized with DMF (0.5 mL) with 1% Triton X-100 (Sigma-Aldrich). Blood samples were centrifuged immediately after collection to remove the blood cells. The plasma portions were added to DMF (0.5 mL) with 1% Triton X-100. After centrifugation, the supernatant portions were diluted with solution A (99.9% H 2 O with 0.1% TFA) and centrifuged again at 16,000g for 2 min with a nylon filter. The filtrates were analyzed by radio-HPLC under conditions identical to those used for analyzing the original radiolabeled peptide.
Biodistribution Studies. The animal procedures were performed according to a protocol approved by the Stanford University Institutional Animal Care and Use Committee. , and 3 h after injection, the mice were anesthetized with 2% isoflurane and placed near the center of the field of view of the microPET scanner in prone position. Three-minute static scans were obtained, and the images were reconstructed by a two-dimensional ordered subsets expectation maximum (OSEM) algorithm. No background correction was performed. Regions of interest (ROIs; 5 pixels for coronal and transaxial slices) were drawn over the tumors on decay-corrected whole-body coronal images. The maximum counts per pixel per minute were obtained from the ROIs and converted to counts per milliliter per minute using a calibration constant. Tissue density was assumed to be 1 g/mL, and the ROIs were converted to counts per gram per minute. Image ROI-derived %ID/g values were determined by dividing counts per gram per minute by the injected dose. No attenuation correction was performed.
Statistical Methods. Statistical analysis was performed using Student's two-tailed t-test for unpaired data. A 95% confidence level was chosen to determine the significance between groups, with a P value less than 0.05 being indicated as a significant difference. The whole radiosynthesis of 18 (Figure 2A,B) . More than 90% of 18 F-CBT-Z EGFR:1907 remained intact after 1 h incubation in mouse serum, while there was about 75% intact 18 F-CBT-Z EGFR:1907 after 2 h of incubation ( Figure 2C,D) . Next, the in vivo stability studies are shown in Figure 3 . In plasma and tumor, 90% and 85%, respectively, of Al 18 F-NOTA-Z EGFR:1907 remained intact ( Figure 3A ,B) at 1 h after injection, indicating excellent stability in vivo. However, 18 F-CBT-Z EGFR:1907 showed much faster degradation in vivo, with only 40% and 24% of intact tracer product in plasma and tumor, respectively ( Figure 3C,D) .
In Vitro Cell Binding Assays. Cell uptake levels for Al Figure 4A ,C, respectively. Al 18 F-NOTA-Z EGFR:1907 quickly accumulated in A431 cells and reached a highest value of 12% of applied activity at 1 h. A similar cell uptake pattern was observed for 18 F-CBT-Z EGFR:1907 , but the uptake level was much lower than that observed for Al 18 F-NOTA-Z EGFR:1907 at 1 h (7% of applied activity). When both probes were incubated with large excesses of nonradioactive affibody molecules (Ac-Cys-Z EGFR:1907 or Cys-Z EGFR:1907 ), their uptake levels in A431 cells were significantly inhibited (P < 0.05) at all incubation time points ( Figure 4A,C) .
The binding affinity of Al 18 F-NOTA-Z EGFR:1907 and 18 F-CBT-Z EGFR:1907 to EGFR was determined through the receptor saturation assay. As shown in Figure 4B, EGFR-binding specificity and affinity, which warranted their further evaluation in vivo.
In Vivo Biodistribution Studies. (Table 1) .
For the in vivo blocking study, coinjection of an excess (300 μg) of unlabeled Ac-Cys-Z EGFR:1907 or Cys-Z EGFR:1907 resulted in significant (P < 0.05) reduction in tumor uptake to 1.78 ± 0.33 and 2.34 ± 0.21 %ID/g for Al 18 F-NOTA-Z EGFR:1907 and 18 F-CBT-Z EGFR:1907 , respectively. Liver uptake also significantly (P < 0.05) decreased to 3.34 ± 0.37 and 2.01 ± 0.45 %ID/g for Al 18 F-NOTA-Z EGFR:1907 and 18 F-CBT-Z EGFR , respectively. For 18 F-CBT-Z EGFR:1907 , kidney uptake also significantly decreased from 8.12 ± 1.0 to 4.26 ± 0.96 %ID/g (P < 0.05). However, for Al 18 F-NOTA-Z EGFR:1907 , kidney uptake did not significantly change in the blocking group (112.27 ± 12.57 vs 104.0 ± 15.58 %ID/g, P > 0.05).
Small-Animal PET Imaging. PET images acquired at 1, 2, and 3 h after injection are shown in Figure 5 . Al Figure 5) . A quantitative analysis of the PET images showed significantly (P < 0.05) lower tumor uptake for mice injected with 300 μg blocking dose when compared to a 30 μg spiking dose at all time points for both probes ( Figure 6 ).
■ DISCUSSION
EGFR-targeted PET imaging is a promising tool to provide a real-time assay of EGFR expression in all tumor sites (primary and metastatic lesions) in living subjects. EGFR-targeted PET probes could not only be used for early detection of EGFR positive tumor recurrence and stratification of cancer patients but also for dose optimization of EGFR targeted therapy and monitoring the efficacy of EGFR-based tumor treatment. Preclinical literature data suggests that radiolabeled affibody molecules have superior imaging properties and higher sensitivity to detect EGFR in comparison with monoclonal antibodies and their fragments due to their small size (7 kDa), as well as excellent tumor targeting and retention, and rapid blood clearance. 8 Furthermore, 18 F, the most commonly used PET radionuclide, is widely available and presents almost ideal imaging properties, making this radionuclide highly clinically relevant. Combining the aforementioned optimal clinical characteristics to develop an imaging agent is significantly F-CBT-Z EGFR:1907 uptake was observed in A431 tumor of the blocked group (300 μg) (P < 0.05). Student's unpaired two tailed t-test was conducted. P < 0.05 was considered significant (for each group, n = 4).
b P < 0.05, comparing 30 μg spike and 300 μg (blocking) of dose tracer biodistribution at 3 h after injection with Al 18 F-NOTA-Z EGFR:1907 . c P < 0.05, comparing 30 μg spike and 300 μg (blocking) of dose tracer biodistribution at 3 h after injection with 18 12 However, the 18 F labeling strategies used in that work involved lengthy (3 h) and tedious multistep radiosynthetic procedures. Moreover, it is very challenging to adapt these radiosynthetic processes into a fully automated radiosynthetic platform, which creates a considerable technical barrier for using these affibody-based PET probes in the clinical setting. Very recently, we have successfully used two methods for RGD peptide radiofluorination ( 18 F-AlF-NOTA and 18 F-CBT) in no more than two radiosynthetic steps within 40 and 120 min, respectively. 16, 18 These recently described strategies provide straightforward, quicker, and powerful 18 F labeling methods to radiofluorinate biomolecules for in vivo molecular imaging applications.
In the present study, only a 1-pot reaction was involved in the procedures to obtain Al 18 F-NOTA-Z EGFR:1907 in a total preparation time of 40 min, with a decay-corrected yield at the end of synthesis of 15%. F-CBT-RGD 2 (80%). 16 It is likely that the lower radiochemical yields observed were due to the fact that the concentration of the affibody molecules (Ac-Cys-Z EGFrefR:1907 or Cys-Z EGFR:1907 ; 0.84 or 0.11 mmol/L) was much lower than that of the peptides RGD 2 (36.6 or 3.55 mmol/L). Further optimization of our current labeling procedure is under investigation and may result in a higher radiolabeling yield of Al rapidly localizes in A431 tumors and shows good tumor uptake, retention, and tumor-to-muscle ratios, allowing clear visualization of A431 tumors by PET at even 1 h postinjection. The highest uptake observed in the kidneys and the liver is mainly attributed to the fact that they are the major organs responsible for metabolism and clearance. High kidney uptake could be associated with radiolabeled affibody molecules being reabsorbed by the organ. Additionally, liver uptake might be increased due to the fact that this organ also highly expresses EGFR. 12 The in vivo EGFRbinding specificity of Al 18 F-NOTA-Z EGFR:1907 was also confirmed by the reduced A431 tumor and liver uptake observed after coinjection with 300 μg of Ac-Cys-Z EGFR:1907 . Moreover, low radioactivity levels were found in the lung, intestine, spleen, and stomach. The low uptake of Al 18 F-NOTA-Z EGFR:1907 in these normal organs makes the PET probe a potential agent to detect primary or metastatic tumors expressing EGFR in the abdomen and lung region. Only low activity was observed in the brain, suggesting that Al 18 F-NOTA-Z EGFR:1907 cannot penetrate through the blood−brain barrier. Interestingly, the kidney uptake of Al 18 F-NOTA-Z EGFR:1907 was not reduced by the unlabeled affibody at all the time points, whereas 18 F-CBT-Z EGFR:1907 was moderately blocked at late time point (3 h) but not at early time points (1 and 2 h). These data suggest the kidney uptake of two probes is not likely receptor mediated. The blocking effort for 18 F-CBT-Z EGFR:1907 at 3 h p.i. may be somewhat linked to the in vivo instability of 18 F-CBT-Z EGFR:1907 . Further studies are required to reveal the observations. Overall, these results indicate that Al 18 F-NOTA-Z EGFR:1907 is characterized by a relatively easy preparation, favorable pharmacokinetic properties, and high specificity for EGFR, which render it a useful agent for in vivo imaging of EGFR positive tumors and related applications.
In contrast, the performance of 18 F-CBT-Z EGFR:1907 in vivo was not ideal: relatively high uptake in most normal tissues (such as brain, pancreas, spleen, intestine, blood, muscle, lung, and spleen), especially the remarkably high uptake in bone (13.0 ± 2.37 %ID/g), suggests in vivo release of 18 F-fluoride (Table 1) . In fact, bone uptake of 18 F-CBT-Z EGFR:1907 was about 3-fold higher than that observed for Al 18 F-NOTA-Z EGFR:1907 . Also, the in vitro stability and metabolite analysis studies, where only about 75%, 40%, and 24% of 18 F-CBT-Z EGFR:1907 was intact after 2 h of serum incubation or in plasma and tumor in vivo at 1 h after injection, suggest that 18 F-CBT-Z EGFR:1907 is not stable in vivo. The kidney and the liver showed the lowest uptake (8.12 ± 1.0 and 3.08 ± 0.15 %ID/g) at 3 h after injection. These results are in agreement with our previous data 17 indicating that polar metabolites clear more rapidly from blood.
NOTA has already been coupled to affibody molecules (Z HER2:2395 and Z HER2:S1 ) and the conjugates radiolabeled with 111 In, 68 Ga, and 18 F for HER2 imaging. 17, 21 Our data are generally consistent with the findings reported in these published studies. For example, it was reported that Al 18 F-NOTA-Z HER2:2395 displayed uptake of 4.4 ± 0.8 and 4.9 ± 0.7 %ID/g in SKOV3 tumors at 1 and 4 h after injection, respectively, whereas the corresponding levels in the kidneys were high (about 140 and 150 %ID/g, from Figure 3 ) and in the bone low (1 %ID/g, from Figure 3) . 17 In the present study, the uptake of Al 18 F-NOTA-Z EGFR:1907 in A431 tumors at 3 h after injection were 4.77 ± 0.34 %ID/g, and the corresponding levels in kidney and bone were 112.27 ± 12.57 and 1.75 ± 0.35 %ID/g, respectively. Overall, Al 18 F-NOTA radiolabeled affibody molecules rapidly accumulated in tumors, with high uptake and good tumor-to-normal tissue ratios and low uptake in the bone indicating stable complexation in the form of Al 18 F by the NOTA chelator. However, they typically showed high uptake in the kidneys as well, probably because radiolabeled affibody molecules were excreted and reabsorbed by the kidneys. In order to minimize the reabsorption of affibody molecules by the kidneys, the pharmacokinetics could be further improved with strategies such as the use of positively charged amino acids, gelofusin, or albumin fragments. 22 F-NOTA-Z EGFR:1907 had a lower tumor uptake (4.77 ± 0.36 vs 8.06 ± 1.44 %ID/g) at 3 h after injection, probably due to the effect of different 18 Fradiolabeling group. In our previous study, 16 we had also successfully developed 18 F-CBT-RGD 2 and 18 F-CBT-RLuc. Both probes demonstrated high levels of tumor accumulation and favorable pharmacokinetic properties. However, in the present study, it has been found that 18 F-CBT-Z EGFR:1907 was degraded in vivo. Therefore, great efforts will be focused on introducing appropriate molecular modifications, such as the use of more stable D-amino acids for L-amino acids, the use of pseudopeptide bonds, 25 modifying synthetic environment, etc.
■ CONCLUSIONS
Two strategies for 18 F-labeling affibody molecules have been successfully developed with either NOTA or CBT coupling to affibody molecules that contain an N-terminal cysteine as two model platforms. These two methods can potentially be translated to other applications. High activities of the probes can be reliably obtained in a relatively short radiosynthesis time. Biodistribution and small-animal PET imaging studies demonstrated that Al 18 F-NOTA-Z EGFR:1907 is a promising PET probe for imaging EGFR expression in living mice. In contrast, 18 
